Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
BorgWarner heads into its October 29 earnings with a high-profile analyst upgrade, falling short interest, and options markets turning decisively bullish, all at the same time.
The most important development this week came from Morgan Stanley. Andrew Percoco upgraded BWA to Overweight from Equal-Weight on October 6, raising his price target from $71 to $95. That is a 34% target lift, a move that changes the story. The stock closed at $63.36 on October 6, up 5.1% on the day and 4.0% on the week. UBS followed the next morning by trimming its target modestly from $95 to $91 while holding its Buy rating, a small adjustment that barely dents the bullish tone. The broader analyst picture is firmly positive: Barclays and JP Morgan both lifted targets after the August earnings print, and RBC initiated with an Outperform in September. The mean target from those combined moves sits near $81, implying roughly 28% upside from the current price. No recent downgrades appear on the register.
Options positioning reflects the same bullish turn. The put/call ratio has collapsed to 0.29, well below the 20-day average of 0.46, almost one standard deviation lighter on puts than usual. That is a sharp reversal from mid-September, when the PCR hit a 52-week high of 0.78 and traders were piling into downside protection. The rotation out of puts and into calls since late September lines up almost exactly with the stock's recovery and the run-up to the Morgan Stanley upgrade. With the 52-week PCR low at 0.09, there is room for positioning to extend further in that direction, but the shift is already notable.
Short interest is not the story here. At 2.9% of the free float, the short position is low and falling fast, down more than 20% over the past month. The lending market confirms the lack of conviction among bears: borrow costs are negligible at 0.46%, and availability is exceptionally loose at 3,225%, meaning for every share currently lent out, more than 32 sit available in the pool. That compares to a 52-week tightest reading of 745% availability, itself a loose market by most standards. There is simply no squeeze dynamic and no meaningful short overhang to consider.
The valuation picture is sober but not demanding. BWA trades at around 11x trailing earnings and 6.7x EV/EBITDA, with the EV/EBITDA multiple up modestly over the past month as the stock recovered. Factor scores are unremarkable across most dimensions: EPS momentum ranks near the sector median, forward earnings growth sits in the bottom third of the universe, and the analyst recommendation differential is essentially flat. The one standout is the dividend score at the 89th percentile, though the dividend history in the data runs only to 2022 and should not be treated as current guidance. The ORTEX short score of 34.6 is stable and low, broadly consistent with the low-short-interest, loose-borrow picture.
Insider activity over the trailing 90 days is net negative, with roughly $5.8 million in net sales. The largest single line was a block sale from EVP and General Counsel Tonit Calaway across multiple August transactions totalling over $4.5 million. A director, Rajesh Kalathur, bought nearly $500,000 worth of stock on August 19 at around $67.60, the sole material open-market purchase in the period. None of the sales were declared under a 10b5-1 plan, which makes them discretionary, though the cluster in August came when the stock was trading above current levels and shortly after BorgWarner's Q2 results. Victory Capital is the most active institutional name in the register, adding 1.9 million shares in its latest reported period, a move worth watching against the backdrop of the Morgan Stanley upgrade.
BWA last reported on August 5 and the stock gained 4.4% the next day, extending to a 9.2% five-day gain. The Q3 report is due October 29, roughly three weeks out. With shorts retreating, options skewing call-heavy, and the Street's largest recent move a significant upgrade, the October 29 print will be measured primarily against rising expectations rather than a low bar.
See the live data behind this article on ORTEX.
Open BWA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
